Total for the last 12 months
number of access : ?
number of downloads : ?
ID 116746
Author
Bando, Hiroshi Tokushima University|Japan Low Carbohydrate Diet Promotion Association KAKEN Search Researchers
Keywords
semaglutide
Rybelsus
Peptide InnOvatioN for Early diabEtes tReatment (PIONEER)
absorption enhancer sodium N-(8-[2-hydroxybenzoyl] amino) caprylate
Novo Nordisk
Content Type
Journal Article
Description
Glucagon-Like Peptide 1 receptor agonist (GLP-1RA) have been recently effective for diabetes. Among them, subcutaneous injection and oral form of semaglutide (Rybelsus) are in focus, in which the latter has been examined in the Peptide InnOvatioN for Early diabEtes tReatment (PIONEER) studies. Rybelsus could been invented for absorption enhancer sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, due to 30-year process of innovation by Novo Nordisk. It shows clinical effects for diabetes and obesity. For PIONEER 9 and 10 trials, efficacy and safety were shown for 3, 7 or 14 mg of Rybelsus equivalent to subcutaneous liraglutide and subcutaneous dulaglutide for 52 weeks.
Journal Title
International Journal of Endocrinology and Diabetes
ISSN
26943875
Publisher
Pubtexto Publishers
Volume
5
Issue
1
Start Page
130
Published Date
2022-01-28
Rights
This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
DOI (Published Version)
URL ( Publisher's Version )
FullText File
language
eng
TextVersion
Publisher
departments
Medical Sciences